Literature DB >> 29112559

Do Moderate Surgical Treatment Delays Influence Survival in Colon Cancer?

Kerollos Nashat Wanis1, Sanjay V B Patel, Muriel Brackstone.   

Abstract

BACKGROUND: Studies examining treatment delay and survival after surgical treatment of colon cancer have varied in quality and outcome, with little evidence available regarding the safety of longer surgical treatment wait times.
OBJECTIVE: Our study examined the effect of surgical treatment wait times on survival for patients with stage I to III colon cancer.
DESIGN: A subset cohort analysis was performed using data from a prospectively maintained database. SETTINGS: The study was conducted at a tertiary referral center. PATIENTS: Data on all of the patients undergoing elective surgery for stage I to III colon cancer from 2006 to 2015 were collected from a prospectively maintained clinical and administrative database. MAIN OUTCOME MEASURES: We examined the impact of prolonged wait time to surgery on disease-free and overall survival. Patients were divided into 2 groups based on a treatment wait time of ≤30 or >30 days and were compared using a Cox proportional hazards model. A subgroup analysis was performed using alternative treatment delay cutoffs of 60 and 90 days.
RESULTS: There were 908 patients with stage I to III colon cancer treated over the study period, with a median treatment wait time of 38 days (interquartile range, 21-61 days); 368 patients were treated within 30 days, and 540 were treated beyond 30 days from diagnosis. In adjusted multivariate analysis, a treatment delay of >30 days was not associated with decreased disease-free survival (HR = 0.89 (95% CI, 0.61-1.3); p = 0.52) or overall survival (HR = 0.82 (95% CI, 0.63-1.1); p = 0.16). Likewise, subgroup analysis using alternative treatment delay cutoffs of 60 and 90 days did not demonstrate an adverse effect on survival. LIMITATIONS: This study was limited by retrospective analysis.
CONCLUSIONS: Despite longer median treatment wait times from diagnosis to surgery, with the majority of patients exceeding 30 days and many experiencing delays of 2 to 3 months, no adverse impact on survival was observed. Patients who require additional consultations or investigations preoperatively may safely have their surgery moderately delayed to minimize their perioperative risk without any evidence that this will compromise treatment outcomes. See Video Abstract at http://links.lww.com/DCR/A397.

Entities:  

Mesh:

Year:  2017        PMID: 29112559     DOI: 10.1097/DCR.0000000000000857

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

1.  The Impact of Delays to Definitive Surgical Care on Survival in Colorectal Cancer Patients.

Authors:  Maude Trepanier; Tiffany Paradis; Araz Kouyoumdjian; Teodora Dumitra; Patrick Charlebois; Barry S Stein; A Sender Liberman; Kevin Schwartzman; Franco Carli; Gerald M Fried; Liane S Feldman; Lawrence Lee
Journal:  J Gastrointest Surg       Date:  2019-07-31       Impact factor: 3.452

Review 2.  Conflicting Guidelines: A Systematic Review on the Proper Interval for Colorectal Cancer Treatment.

Authors:  Charlotte J L Molenaar; Loes Janssen; Donald L van der Peet; Desmond C Winter; Rudi M H Roumen; Gerrit D Slooter
Journal:  World J Surg       Date:  2021-04-03       Impact factor: 3.352

3.  [Impact of the pandemic on surgical activity in colorectal cancer in Spain. Results of a national survey].

Authors:  Fernando de la Portilla de Juan; María Luisa Reyes Díaz; Irene Ramallo Solía
Journal:  Cir Esp       Date:  2020-09-01       Impact factor: 1.653

4.  Longer time-to-treatment but better survival for colorectal cancer patients presumptively not diagnosed in a hospital.

Authors:  Cara L Frankenfeld; Timothy F Leslie; Nirup M Menon
Journal:  Cancer Causes Control       Date:  2021-06-23       Impact factor: 2.506

Review 5.  Delay to elective colorectal cancer surgery and implications for survival: a systematic review and meta-analysis.

Authors:  Thomas M Whittaker; Mohamed E G Abdelrazek; Aran J Fitzpatrick; Joseph L J Froud; Jack R Kelly; Jeremy S Williamson; Gethin L Williams
Journal:  Colorectal Dis       Date:  2021-03-25       Impact factor: 3.917

6.  What's the magic number? Impact of time to initiation of treatment for rectal cancer.

Authors:  Gretchen C Edwards; Adriana C Gamboa; Michael P Feng; Roberta L Muldoon; Michael B Hopkins; Sherif Abdel-Misih; Glen C Balch; Jennifer Holder-Murray; Maryam Mohammed; Scott E Regenbogen; Matthew L Silviera; Alexander T Hawkins
Journal:  Surgery       Date:  2021-09-24       Impact factor: 4.348

7.  Gastrointestinal Malignancies and the COVID-19 Pandemic: Evidence-Based Triage to Surgery.

Authors:  Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery
Journal:  J Gastrointest Surg       Date:  2020-06-30       Impact factor: 3.452

8.  Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.

Authors:  David Roder; Christos Stelios Karapetis; Ian Olver; Dorothy Keefe; Robert Padbury; James Moore; Rohit Joshi; David Wattchow; Dan L Worthley; Caroline Louise Miller; Carol Holden; Elizabeth Buckley; Kate Powell; Dianne Buranyi-Trevarton; Kellie Fusco; Timothy Price
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

9.  Waiting times for prostate cancer: A review.

Authors:  Giacomo Lazzeri; Gianmarco Troiano; Barbara Rita Porchia; Federica Centauri; Vincenzo Mezzatesta; Giorgio Presicce; Daniela Matarrese; Roberto Gusinu
Journal:  J Public Health Res       Date:  2020-06-04

10.  An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.

Authors:  Koen Degeling; Nancy N Baxter; Jon Emery; Mark A Jenkins; Fanny Franchini; Peter Gibbs; G Bruce Mann; Grant McArthur; Benjamin J Solomon; Maarten J IJzerman
Journal:  Asia Pac J Clin Oncol       Date:  2021-02-10       Impact factor: 1.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.